Combination chemotherapy in histiocytosis X

Area of Science:

• Pediatric Oncology
• Hematology
• Dermatology

Background:

• Histiocytosis X, also known as Langerhans cell histiocytosis (LCH), is a rare clonal proliferative disease.
• Generalized LCH in children presents a significant therapeutic challenge with variable outcomes.

Purpose of the Study:

• To evaluate the efficacy and toxicity of a combination chemotherapy regimen in pediatric patients with generalized histiocytosis X.
• To compare treatment outcomes based on patient age.

Main Methods:

• A cohort of twenty-five children with generalized histiocytosis X received treatment with cyclophosphamide, vinblastine, and prednisone.
• Patient responses were categorized as complete response (CR), partial response (PR), improvement, or no response.

Main Results:

• Overall response rate was 64% (16/25 patients).
• Children over 1 year of age demonstrated higher response rates compared to historical data with single agents.
• Twelve patients achieved disease-free status for 10-50 months.
• Infants (less than 1 year) showed very poor response rates and high toxicity; two infants achieved CR with alternative therapies.

Conclusions:

• Combination chemotherapy offers a potential benefit for children over one year with generalized histiocytosis X.
• Treatment in infants is associated with significant toxicity and limited efficacy, warranting cautious approach.
• Future research should balance the benefits of rapid disease control with potential long-term adverse effects of combination chemotherapy.